Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ASPH | Q12797 | 3/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.44 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232024 | 0.84 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2ASPHKDM8 | |
| SCHEMBL29978511 | 0.84 | ALDH1A1 (0.38) | KDM4EALDH1A1SMN1; SMN2GABRPGABRD | |
| SCHEMBL13859136 | 0.84 | ALDH1A1 (0.38) | KDM4EALDH1A1SMN1; SMN2GABRPGABRD | |
| SCHEMBL7083217 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2ASPHKDM8 | |
| SCHEMBL17841571 | 0.82 | POLB (0.38) | KDM4EALDH1A1P4HTMP4HA1MIF | |
| SCHEMBL3120938 | 0.82 | TSHR (0.42) | KDM4EALDH1A1L3MBTL1GABRPGABRD | |
| SCHEMBL28635523 | 0.81 | KDM4E (0.48) | KDM4EALDH1A1SMN1; SMN2ASPHKDM8 | |
| Potassium Ion SCHEMBL13731040 | 0.81 | KDM4E (0.36) | KDM4EALDH1A1P4HTMHCAR2GABRP | |
| SCHEMBL12384971 | 0.80 | UHRF1 (0.52) | KDM4EALDH1A1SMN1; SMN2ASPHKDM8 | |
| SCHEMBL24665060 | 0.79 | HPGD (0.36) | KDM4EALDH1A1L3MBTL1MAPK1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEONE MEDICINES I GMBH (CH) | 2026-04-28 | — | — | US | disclosed |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-03-19 | — | — | US | disclosed |
| US-12516044-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| EP-3750887-B1 | BIARYL DERIVATIVES AND THEIR PHARMACEUTICAL APPLICATION FOR THE TREATMENT OF PD-1/PD-L1 SIGNAL PATHWAY-MEDIATED DISEASES | ABBISKO THERAPEUTICS CO LTD (CN) | 2025-05-28 | — | — | EP | disclosed |
| CN-113423708-B | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2025-04-22 | — | — | CN | disclosed |
| US-20240390387-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-11-28 | — | — | US | disclosed |
| US-12102641-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-10-01 | — | — | US | disclosed |
| US-20240287062-A1 | NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2024-08-29 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| EP-2195311-B1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| CN-101965346-A | Novel pyrimidine-pyridine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-02-02 | — | — | CN | disclosed |
| US-20100331372-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-12-30 | — | — | US | disclosed |
| EP-2262800-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-2252609-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009109907-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109872-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | KDM4E 2583/4885ALDH1A1 1801/4885SMN1; SMN2 2800/4885 |
| US-20100331372-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | IL2, FCGRT, CD4 | KDM4E 965/4885ALDH1A1 1058/4885SMN1; SMN2 4113/4885 |
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR8, TLR1 | KDM4E 2199/4885ALDH1A1 1253/4885SMN1; SMN2 1682/4885 |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | KDM4E 1861/4885ALDH1A1 1658/4885SMN1; SMN2 4245/4885 |
| US-12102641-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | BRD4, BRD1, BRD2 | KDM4E 81/4885ALDH1A1 4137/4885SMN1; SMN2 2513/4885 |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | KDM4E 146/4885ALDH1A1 529/4885SMN1; SMN2 240/4885 |
| US-20240390387-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | KDM4E 81/4885ALDH1A1 4137/4885SMN1; SMN2 2513/4885 |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | MSR1, NR3C1, CCR1 | KDM4E 4270/4885ALDH1A1 868/4885SMN1; SMN2 3526/4885 |
| US-20240287062-A1 | NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES | BRAF, NRAS, ABL1 | KDM4E 1356/4885ALDH1A1 1865/4885SMN1; SMN2 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.